PRINCETON, NJ – Jan. 10, 2017 – Certara today announced that it has released version 16 of its Simcyp Population-based Simulator. The Simcyp Simulator is the pharmaceutical industry’s most sophisticated platform for determining first-in-human dose selection, designing more efficient and effective clinical studies, evaluating new drug formulations, and predicting drug-drug interactions (DDIs) and pharmacokinetic (PK) outcomes in clinical populations.
PRINCETON, NJ – Dec. 6, 2016 – Certara today announced that it is establishing a new Quantitative Systems Toxicology (QST) Initiative. That initiative, which will be managed by the company’s Simcyp division, leverages its Quantitative Systems Pharmacology (QSP) expertise.
PRINCETON, NJ – Dec 7, 2016 – Certara today announced the launch of its Phoenix WinNonlin Validation Suite 7.0. This application simplifies and expedites the validation process for Phoenix WinNonlin software, which is used extensively for drug regulatory submissions.
PRINCETON, NJ – Nov. 10, 2016 – Certara today announced that the U.S. Environmental Protection Agency (EPA) is using its Simcyp Population-based Simulator to support the Agency’s high-throughput toxicity testing program.
PRINCETON, NJ – Nov. 9, 2016 – Certara announced that it will be chairing three sessions and participating in six more at the 2016 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting & Exposition.
Certara’s Simcyp Division Awarded Modeling and Simulation Grant from the US FDA’s Office of Generic Drugs
PRINCETON, NJ – Oct. 19, 2016 – Certara announces that the Office of Generic Drugs (OGD), US Food and Drug Administration (FDA) has awarded it a multi-year research grant to create and validate a physiologically-based pharmacokinetic (PBPK) modeling and simulation framework that complements existing models within the Simcyp Population-based Simulator.
PRINCETON, NJ – Oct. 13, 2016 – Certara, the leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, today announced that Peking Union Medical College (PUMC) Hospital in Beijing, China, and Keio University in Tokyo, Japan have become Phoenix Centers of Excellence.
PRINCETON, NJ – Oct. 6, 2016 – Certara announces that Kelley Kendle, president of Synchrogenix, its medical and regulatory writing consultancy, has been named a Delaware Business Times (DBT) 40 honoree. This is an annual listing of Delaware’s influential achievers and innovators under the age of 40.
Inaugural Certara Biomedical Research Scholarship Awarded by International Biomedical Research Alliance
PRINCETON, NJ – Sept. 22, 2016 – Certara today announced that the first Certara Biomedical Research Scholarship has been awarded to the National Institutes of Health (NIH) National Center for Advancing Translational Science (NCATS) on behalf of postgraduate oncology research student David Morse, MPhil, and the research he is conducting in the laboratory of Craig Thomas, PhD.